275 related articles for article (PubMed ID: 36736781)
1. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
[TBL] [Abstract][Full Text] [Related]
2. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
[TBL] [Abstract][Full Text] [Related]
3. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein JD; Lutzko C; Leemhuis T; Zhu X; Pham G; Ray L; Thomas S; Dourson C; Wilhelm J; Lane A; Cancelas JA; Lipps D; Ferrell J; Hanley PJ; Keller MD; Bollard CM; Wang YM; Davies SM; Nelson AS; Grimley MS
Blood Adv; 2022 May; 6(9):2897-2907. PubMed ID: 35108727
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.
Naik S; Nicholas SK; Martinez CA; Leen AM; Hanley PJ; Gottschalk SM; Rooney CM; Hanson IC; Krance RA; Shpall EJ; Cruz CR; Amrolia P; Lucchini G; Bunin N; Heimall J; Klein OR; Gennery AR; Slatter MA; Vickers MA; Orange JS; Heslop HE; Bollard CM; Keller MD
J Allergy Clin Immunol; 2016 May; 137(5):1498-1505.e1. PubMed ID: 26920464
[TBL] [Abstract][Full Text] [Related]
5. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant.
Jiang W; Clancy LE; Avdic S; Sutrave G; Street J; Simms R; McGuire HM; Patrick E; Chan AS; McCaughan G; Myers N; Micklethwaite KP; Antonenas V; Selim AG; Ritchie D; Bateman CM; Shaw PJ; Blyth E; Gottlieb DJ
Blood Adv; 2022 Sep; 6(17):4949-4966. PubMed ID: 35819448
[TBL] [Abstract][Full Text] [Related]
6. Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease.
Kinoshita H; Mandava M; Jensen-Wachspress M; Lang H; Joy E; Tanna J; McCann CD; O'Brien S; Burnett S; Shibli A; Hoq F; Bhatia M; Hanley PJ; Dávila Saldaña B; Mahadeo KM; Bollard CM; Keller MD; Abraham A
Blood Adv; 2023 May; 7(10):2105-2116. PubMed ID: 36516084
[TBL] [Abstract][Full Text] [Related]
7. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
Keller MD; Hanley PJ; Chi YY; Aguayo-Hiraldo P; Dvorak CC; Verneris MR; Kohn DB; Pai SY; Dávila Saldaña BJ; Hanisch B; Quigg TC; Adams RH; Dahlberg A; Chandrakasan S; Hasan H; Malvar J; Jensen-Wachspress MA; Lazarski CA; Sani G; Idso JM; Lang H; Chansky P; McCann CD; Tanna J; Abraham AA; Webb JL; Shibli A; Keating AK; Satwani P; Muranski P; Hall E; Eckrich MJ; Shereck E; Miller H; Mamcarz E; Agarwal R; De Oliveira SN; Vander Lugt MT; Ebens CL; Aquino VM; Bednarski JJ; Chu J; Parikh S; Whangbo J; Lionakis M; Zambidis ET; Gourdine E; Bollard CM; Pulsipher MA
Nat Commun; 2024 Apr; 15(1):3258. PubMed ID: 38637498
[TBL] [Abstract][Full Text] [Related]
8. Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies.
Quach DH; Lulla P; Rooney CM
Blood; 2023 Feb; 141(8):877-885. PubMed ID: 36574622
[TBL] [Abstract][Full Text] [Related]
9. Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis.
Düver F; Weißbrich B; Eyrich M; Wölfl M; Schlegel PG; Wiegering V
PLoS One; 2020; 15(2):e0228451. PubMed ID: 32017805
[TBL] [Abstract][Full Text] [Related]
10. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
11. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
Leen AM; Bollard CM; Mendizabal AM; Shpall EJ; Szabolcs P; Antin JH; Kapoor N; Pai SY; Rowley SD; Kebriaei P; Dey BR; Grilley BJ; Gee AP; Brenner MK; Rooney CM; Heslop HE
Blood; 2013 Jun; 121(26):5113-23. PubMed ID: 23610374
[TBL] [Abstract][Full Text] [Related]
12. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
Cruz CR; Micklethwaite KP; Savoldo B; Ramos CA; Lam S; Ku S; Diouf O; Liu E; Barrett AJ; Ito S; Shpall EJ; Krance RA; Kamble RT; Carrum G; Hosing CM; Gee AP; Mei Z; Grilley BJ; Heslop HE; Rooney CM; Brenner MK; Bollard CM; Dotti G
Blood; 2013 Oct; 122(17):2965-73. PubMed ID: 24030379
[TBL] [Abstract][Full Text] [Related]
13. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.
Qian C; Campidelli A; Wang Y; Cai H; Venard V; Jeulin H; Dalle JH; Pochon C; D'aveni M; Bruno B; Paillard C; Vigouroux S; Jubert C; Ceballos P; Marie-Cardine A; Galambrun C; Cholle C; Clerc Urmes I; Petitpain N; De Carvalho Bittencourt M; Decot V; Reppel L; Salmon A; Clement L; Bensoussan D
J Hematol Oncol; 2017 May; 10(1):102. PubMed ID: 28482908
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of viral infections among children undergoing hematopoietic stem cell transplant: Α prospective single-center study.
Tsoumakas K; Giamaiou K; Goussetis E; Graphakos S; Kossyvakis A; Horefti E; Mentis A; Elefsiniotis I; Pavlopoulou ID
Transpl Infect Dis; 2019 Aug; 21(4):e13095. PubMed ID: 30993823
[TBL] [Abstract][Full Text] [Related]
15. The effects of β
Kunz HE; Agha NH; Hussain M; LaVoy EC; Smith KA; Mylabathula P; Diak D; Baker FL; O'Connor DP; Bond RA; Katsanis E; Bollard CM; Simpson RJ
Cell Stress Chaperones; 2020 Nov; 25(6):993-1012. PubMed ID: 32779001
[TBL] [Abstract][Full Text] [Related]
16. Applications of virus-specific T cell therapies post-BMT.
Motta CM; Keller MD; Bollard CM
Semin Hematol; 2023 Jan; 60(1):10-19. PubMed ID: 37080705
[TBL] [Abstract][Full Text] [Related]
17. Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients.
Rubinstein JD; Jodele S; Heyenbruch D; Wilhelm J; Thomas S; Lutzko C; Zhu X; Leemhuis T; Cancelas JA; Keller M; Bollard CM; Hanley PJ; Boghdadly ZE; Mims A; Davies SM; Grimley MS; Nelson AS
Transplant Cell Ther; 2022 Feb; 28(2):116.e1-116.e7. PubMed ID: 34785398
[TBL] [Abstract][Full Text] [Related]
18. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
19. Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.
Rubinstein JD; Zhu X; Leemhuis T; Pham G; Ray L; Emberesh S; Jodele S; Thomas S; Cancelas JA; Bollard CM; Hanley PJ; Keller MD; Grimley O; Clark D; Clark T; Lindestam Arlehamn CS; Sette A; Davies SM; Nelson AS; Grimley MS; Lutzko C
Blood Adv; 2021 Sep; 5(17):3309-3321. PubMed ID: 34473237
[TBL] [Abstract][Full Text] [Related]
20. Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.
Qian C; Wang Y; Reppel L; D'aveni M; Campidelli A; Decot V; Bensoussan D
Bone Marrow Transplant; 2018 Feb; 53(2):114-122. PubMed ID: 29058697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]